Evidence supporting secondary prevention strategies.
Currently 14 million individuals in the United States have coronary disease. Within the next 2 decades, this number is expected to increase to 21 million persons. To minimize the excessive risk of recurrent cardiac events in these people, evidence-based, cost-effective prevention strategies must be developed. This review highlights the evidence supporting commonly used means of secondary prevention and is divided into two major sections: lifestyle modifications and pharmacologic interventions. Lifestyle changes discussed include smoking cessation, especially newer pharmacologic adjuncts; the efficacy of dietary interventions; and current inroads into the treatment of depression in recurrent events. Pharmacologic innovations include reexamination of a role for warfarin; continued advances in the treatment of hyper- and dyslipidemias, new roles for beta-blockade in congestive heart failure, and finally a view of future measures, risk and targets of risk intervention.